Myocarditis was previously attributed to an epidemic viral infection. Additional harmful reagents, in addition to viruses, play a role in its etiology. Coronavirus disease 2019 (COVID-19) vaccine-induced myocarditis has recently been described, drawing attention to vaccine-induced myocarditis in children and adolescents. Its pathology is based on a series of complex immune responses, including initial innate immune responses in response to viral entry, adaptive immune responses leading to the development of antigen-specific antibodies, and autoimmune responses to cellular injury caused by cardiomyocyte rupture that releases antigens. Chronic inflammation and fibrosis in the myocardium eventually result in cardiac failure. Recent advancements in molecular biology have remarkably increased our understanding of myocarditis. In particular, microRNAs (miRNAs) are a hot topic in terms of the role of new biomarkers and the pathophysiology of myocarditis. Myocarditis has been linked with microRNA-221/222 (miR-221/222), miR-155, miR-10a*, and miR-590. Despite the lack of clinical trials of miRNA intervention in myocarditis yet, multiple clinical trials of miRNAs in other cardiac diseases have been aggressively conducted to help pave the way for future research, which is bolstered by the success of recently U.S. Food and Drug Administration-approved small-RNA medications. This review presents basic information and recent research that focuses on myocarditis and related miRNAs as a potential novel biomarker and the therapeutics.
· Myocarditis was recently examined quantitatively as inflammation of the heart muscle based on endomyocardial biopsy, and its noninvasive diagnosis remains unsatisfactory.
· Additionally, numerous miRNAs (miR-155, miR-146b, miR-590, miR-221, miR-222, etc.) coupled with inflammation or viral activation have been examined in myocarditis patients or mouse models.
· The recent identification of mmu-miR-721 (has-miR-Chr8: 96), a myocarditis-specific microRNA, demonstrated its potential as an acute myocarditis biomarker.
Graphical abstract.
Introduction
Myocarditis is a broad term for inflammatory disorders of the heart muscles. In his work, Traité des Maladies du Coeur (Treatise on Heart Disease) published in 1749, Jean Baptiste Senac identified inflammation in the heart. Later, Joseph Freidrich Sobernheim coined the term myocarditis to describe cardiomyopathy caused by myocyte inflammation, ischemia, and hypertensive heart disease [1]. Various viral infections in the heart, such as coxsackievirus, echovirus, the mumps virus, influenza virus, measles virus, poliovirus, and smallpox, have been reported during epidemic periods, leading to myocarditis becoming a broader term that covers myocardial infarction, chronic ischemic heart disease, and occasionally, pancarditis or myopericarditis [2,3]. To date, it has been used interchangeably. Recent efforts have been made to clearly describe myocarditis, which is defined as inflammation of the cardiac muscle and recognized as a disease that leads to heart failure [1,4].
Endomyocardial biopsy (EMB) with quantitative standards (≥14 lymphocytes/mm2, including ≤4 monocytes/mm2, with the presence of cluster of differentiation 3–positive T lymphocytes, 7 cells/mm2) and immunohistochemistry assays are used to diagnose myocarditis [3,5]. However, this approach is only acceptable for isolated inflammatory regions, making it difficult to diagnose fulminant myocarditis (FM), which involves widespread inflammation throughout the heart [6,7]. Quantitative cardiac troponin analysis combined with cardiac magnetic resonance imaging (MRI) to assess the injured myocardium can be utilized to noninvasively diagnose myocarditis to overcome localized inflammation, spontaneous resolution, and myocardium sampling difficulties [8-11].
According to the International Classification of Illnesses 9th revision, myocarditis affects approximately 22 per 100,000 individuals worldwide [12,13]. Systematic reviews of the clinical courses of myocarditis patients from the Lombardy registry (443 patients from the Italian region) and 220 cases in 2018, which used combined diagnostic strategies, revealed that left ventricular systolic dysfunction, ventricular arrhythmias, hemodynamic instability, and QRS width should be considered the initial diagnostic factors for FM [14,15].
An estimated, 0.5%–4 % of myocarditis cases progress to heart failure [13]. Myocarditis, which is the leading cause of sudden death among young athletes, is particularly prevalent, accounting for 5%–12% of all deaths [16]. Furthermore, our understanding of the etiology of myocarditis is limited, although we know that it can occasionally resolve spontaneously or result in heart failure, highlighting the need for early diagnosis and accurate comprehension [4].
This review presents basic information and recent research highlights in the field of myocarditis, with a particular focus on disease-specific microRNA (miRNA) expression patterns and the goal of their potential use as alternative prognostic and diagnostic tools to supplement the current standards.
Myocarditis etiology
Infection, autoimmune responses, and toxicity are the 3 most common causes of myocarditis. Among them, viral infections are the most common. Several viruses, including coxsackievirus [17,18], H1N1 influenza [19], adenovirus [20], hepatitis C [21,22], cytomegalovirus [23], echovirus [24], parvovirus B-19, herpes virus [25], and Epstein-Barr virus [26] were detected in heart autopsy samples on a regular and local basis [26]. In addition to viral infectionmediated immune responses, bacterial-driven cases such as Lyme disease (Borrelia burgdorferi) [27] and parasite-mediated Chagas disease (Trypanosoma cruzi) [28] have been reported regularly, as have drug- or vaccine-related cases such as ampicillin or tetracycline [29-31] or smallpox vaccines [32,33].
Amid the recent coronavirus disease 2019 (COVID-19) pandemic, cases of myocarditis reported in people vaccinated with the COVID-19 mRNA vaccine and the relationship between myocarditis after COVID-19 infection and vaccination are under investigation. This finding was supported by 2 major cohort studies. One survey in Israel reported 136 cases of definitive or probable myocarditis within one month of receiving one shot of the vaccine. This study included more than 5 million participants who had received immunization. Of these cases, 135 had a mild or moderate clinical course and one was fatal. After the second dose of the vaccination, a 15 in 100,000 chance of developing myocarditis was assessed in adolescents and young men aged 16–19 years [30]. Similar studies in the United States reported a somewhat lower rate of 5 of 10,000 cases (18- to 24-year-old men). However, all of these cases were less severe than myocarditis caused by direct viral infection. Severe acute respiratory syndrome coronavirus 2 infection results in an 18fold increased risk of myocarditis in the same age group [31].
Two 10-year studies of Koreans included cases of myocarditis in children. Park et al. [34] studied the incidence of myocarditis in Korean children in 2010–2019. This multicenter study included 142 patients with myocarditis/pericarditis. The patients were a mean 5.4 years of age, with males accounting for 61% of the total. Compared to other age groups ranging from 17 days to 17 years of age, the teen years, defined as ages 12–17 years, had the highest prevalence of 1.25 per 1,000 patients. The frequency of occurrence has increased considerably over the last decade from 0.34 in 2010 to 1.25 in 2019. Among the principal etiologies of infections are Mycoplasma pneumoniae, enterovirus, rhinovirus, adenovirus, respiratory syncytial virus, influenza virus, parainfluenza virus, and parvovirus. On rare occasions, adenoviruses and endemic coronaviruses have been observed simultaneously. However, in 60% of patients, no pathogens were detected. Between 2007 and 2016, another study enrolled 1,462 pediatric cases after health insurance evaluations. The annual occurrence has increased from 1.4 to 2.1. Male patients over the age of 13 years were much more numerous in the 2010–2019 survey [35]. The incidence of myocarditis is bimodal, with peaks during infancy and midadolescence, similar to the 2 peaked cardiac growth signals [36,37]. These 2 studies reported a similar trend of myocarditis in Korean children: (1) Its proclivity for growth continues to increase annually; and (2) In midadolescence, boys are more prone to its development.
In Korea, COVID-19 vaccinations for third-year high school students began in July 2021. The incidence of myocarditis was calculated. Myocarditis occurred in 1.97 of every 100,000 cases after the first dose and 3.1 of every 100,000 cases after the second dose per 100,000 vaccine cases. These data were provided concurrently with the incidence in the United States and Israel based on a report from Korea’s Disease Control and Prevention Agency (12-9-21 release). According to this report, myocarditis cases in Korea are approximately 7 times higher than that described in the United States or 3 times more than that in Israel for the first dose. However, the incidence after the second immunization dose was comparable to or lower than that of other 2 countries. Notably, Israel’s incidence following the second dose is 2.77 times higher than that in Korea. Table 1 illustrates a three-nation comparison focusing on midadolescent age cases of the myocarditis after vaccinations.
Myocarditis pathogenesis
Because viral infection is the most common cause of myocarditis, viral infection-mediated pathology is discussed here. These studies are mostly based on the pathophysiological understanding of the murine model. The first step is linked to viral replication in the heart, resulting in cellular rupture, an antigenindependent and innate immune response. Consequently, adaptive immune responses are triggered in antigen-presenting cells, resulting in the production of antigen-specific antibodies. Autoimmune reactions and cellular damage propagate during this stage as cardiac proteins are released through cardiomyocyte rupture. Finally, the replacement of collagen with dead myocardium results in persistent inflammation and fibrosis [38].
There is also disagreement regarding whether viral infection is a direct pathogenic cause of cardiac injury. It is a situation in which a virus triggers immune responses to cause cardiomyocyte injury, or that cardiomyocyte injury is caused by viral infection. The presence of the viral genome in the myocardium of patients with chronic inflammatory cardiomyopathy, rather than acute myocarditis, is suggested [39,40]. Reports on FM associated with viral infection frequently adopted nasopharyngeal swabs for the diagnosis of viral infection [41]. The hs-troponin level was also elevated in COVID-19 patients, suggesting that the virus generated aberrant immune-mediated inflammatory responses rather than viral-directed myocyte damage [42-44]. Understanding the pathophysiology, whether the virus is directly or indirectly involved, is critical for immunosuppression because its role is also conflicting [3,45]. The use of immunosuppressive medication should generally be validated by polymerase chain reaction to ensure that the condition is not an active infection in EMB [3].
Patients with acute myocarditis alone or in combination with autoimmune responses were also identified among those who received immuno-checkpoint inhibitor (ICI) medications [46,47]. Since many cancer patients have just begun to utilize ICI treatment and its estimated correlation with myocarditis is 1.14%, it may become a subtype of myocarditis with distinct age and inflammatory type in the near future [46].
Myocardial inflammation and the cellular compartment
Idiopathic, autoimmune, and infectious are the 3 types of myocardial inflammation [4]. Interactions between several cellular compartments causes myocardial inflammation. T-, B-, and lymphoid-derived cells, such as macrophages, dendritic cells, granulocytes, mast cells, and immature precursor cells, all contribute to the differentiation of inflammatory cells and myofibroblasts [4]. Caspase-1, n-terminal PYRIN PAAD DAPIN and c-terminal caspase-recruitment domain containing, and nucleotide-binding oligomerization domain-like receptor pathways play a role in the production of proinflammatory cytokines during this process. Toll-like receptors (TLRs) have also been implicated in the activation of innate immune responses in the early stages [48]. TLR3 polymorphism have been linked to enteroviral myocarditis [49]. Tumor necrosis factor-α (TNF-α) and interleukin (IL)-1β are also released in the myocardium by the TLR pathway [50,51].
Inflammatory cell invasion is aided by macrophages. Because Ly6Chi inflammatory macrophages are found in the early stages of cardiac damage, their blockade has been used to treat autoimmune myocarditis [52-54]. The Ly6Clow M2 macrophage is a critical factor in the transition from acute to pathological remodeling via myofibroblast replacement [55,56]. Thymic resistance to alpha-myosin heavy chain (MyHC) causes, at least in part, T-cell function to quell autoimmune responses after clearing infections [57,58]. Overexpressing alpha-MyHC promoterspecific T-cell receptors were designed for a mouse autoimmune myocarditis model based on this understanding [59]. The release of cytokines by T cells determines myocarditis progression. T-helper (Th) type 1 cells produce interferon gamma, while Th2 cells produce IL-4, -5, and -13. Type 17 helper T (Th17) cells mainly produce IL-17 [60-63].
While lymphoid-derived cells are involved in adaptive immune responses, endothelial cells act as barriers preventing circulating bone marrow-derived cells from entering the heart. Interstitial cell types, such as fibroblasts, myofibroblasts, and stromal cells, act as a matrix to modify the inflammatory phenotype via local cues. During pathogenesis, the cardiomyocyte compartment is also involved in early infection and adaptive responses such as altered calcium signaling or hypertrophy [64,65]. Both direct and indirect cross-talk was used to orchestrate these interactions (Table 2) [66].
Myocarditis and miRNA
There has been research on the posttranscriptional modulation of cardiac immunological responses, including miRNA-mediated controls. MiRNAs are 22-nt single-strand RNAs that complementarily base pair with mRNAs, primarily but not exclusively in the 3′ untranslated region, to govern translation by a minimum 6-mer base-pairing. This is generally a translational repressor [67,68].
The importance of miRNAs in myocardial specification and cardiac development, as well as in cardiac disorders such as cardiac hypertrophy, myocardial infarction, arrhythmia, myocarditis, coronary artery disease, and heart failure, has been recognized [69-71]. Circulating miRNAs in the blood have been used to identify novel biomarkers in addition to their role in the heart [72,73]. MED13 and miR-208a are 2 of the most notable regulators of metabolic homeostasis via systemic control [74]. Table 3 summarizes the miRNAs in heart disorders, including myocarditis.
Several miRNA profiling studies have been conducted. A total of 107 miRNAs were dysregulated in human right ventricular myocarditis samples [75]. The inhibition of miR-155, miR-21, and miR-146b, for example, reduced cardiac inflammation and myocardial damage in a coxsackievirus B3 (CVB3) animal model and mouse autoimmune studies [76-79]. Furthermore, miR-590-3p overexpression reduced disease by repressing nuclear factor kappa B (NF-κB) expression and turning off IL-6/TNF-α expression by targeting NF-κB [80].
Patients with myocarditis were profiled for various CVB3 clearance conditions. Patients with defective cardiac function under protracted viral accumulation (CVB3) had a greater expression of 8 miRNAs, including miR-135b, -155, -190, -422a, -489, -590, -601, and -1290 [81]. Circulating miRNAs in the blood have been investigated as a means of diagnosis or prognosis, while myocarditis is present. miR-208 and miR-499 were overexpressed in the blood plasma during acute myocarditis. However, misregulation of these 2 miRNAs has been documented in acute ischemia and hypertensive disorders, implying that other defining factors may be required [82,83]. Cellular release in response to inflammation could explain the mixed expression of these 2 miRNAs [82].
In mouse myocarditis model studies involving enterovirus CVB3, the dysregulation of miR-221/222 by targeting ETS1/2, interferon regulatory factor 2, and B-cell lymphoma 2 (Bcl2)like-11 maintained prolonged cardiac viremic states and activate inflammatory and injury pathways by targeting ETS1/2, interferon regulatory factor 2, and Bcl2-like-11 [84]. MiR-155 uses a similar regulatory mechanism to activate immune responses such as T cells and monocytes by targeting PU.1 and suppressor of cytokine signaling 1 [84,85].
Recent studies using a murine myocarditis model revealed the induction of cardiac myosin-specific Th17 lymphocytes in a myocarditis-specific manner, turning on as early as 3 days after onset, which differs from the response of myocardial infarction, which also showed Th17 cell upregulation later in the disease course. Using a murine model, the authors validated Th17 cell upregulation of mmu-miR-721 from 27 dysregulated miRNAs. The authors stated that dysregulation of the human version of miR-721, has-miR-Chr8:96, was confirmed in a large human cohort study that included 42 myocarditis patients (based on cardiac MRI diagnosis), 90 myocardial infarction patients, and 80 healthy participants, implying that it could be used as a biomarker for acute myocarditis [86].
A total of 113 miRNAs were differentially expressed in a murine myocarditis model using Trypanosoma cruzi. The authors reported that miR-146b, miR-21, miR-142-3p, miR-142-5p, miR-145-5p, and miR-149-5p were correlated with disease severity [79].
MiRNAs as medications for cardiac diseases
Although antisense RNAs as a novel mechanism for medication have been explored since 1978 [87], the success of partisiran, a short RNA drug that mimics siRNAs with pharmacological features to treat polyneuropathy, has only recently become beneficial for treatment [88-90].
Small RNA therapies, either inhibiting or activating, are likely to be actively developed for the medical intervention of heart disorders [90-93]. In the pharmaceutical industry, there are 2 primary types of antitechnologies that repress miRNAs. The first is antagomir [94], a cholesterol-based modified RNA, while the second is locked nucleic acid (LNA)-modified RNA [70, 95]. AntimiR-92a, also known as MRG-110, is an LNA/DNA mixed, phosphorothiorate linkage, and 16-nucleic acid medication that was administered intravenously and had a repressive efficacy of up to 2 weeks with a single dose in healthy humans [96]. Taubel et al. [97] used an antisense LNA method to block miR-132-3p in patients with heart failure. This group previously demonstrated that LNA-based chemical modification approaches effectively lowered miRNA levels while maintaining Watson-Crick basepairing [98].
Furthermore, scientists demonstrated that miR-132-3p repression clearly improved the heart failure mouse model [99], which was then expanded into a large animal setting as a preclinical trial to determine the dosage with enhanced cardiac functions [100]. With this excellent research background, the authors assessed the efficacy of LNA-miR-132-3p (CDR132L) for the first time by examining heart failure biomarkers, cardiac fibrosis, QRS narrowing, and left ventricular ejection fraction. For 28 patients, 4 dosage groups with a maximum dose of 10 mg/kg administered every 4 weeks were created. Efficacy assessments were underpowered in the phase 1b trial due to the research design and small patient cohort, but this study clearly demonstrated the safety of a dose-dependent reduction of plasma miR-132-3p expression level and encouraged the next stage in the development of this innovative drug [97].
MiRNAs as biomarkers for cardiac diseases
In both experimental animals and humans, miRNA expression profiling has been shown to reflect disease status and/or progression. Misregulation of miR-195 and miR-21 was observed for the first time in mouse models of heart hypertrophy [101]. Since then, a large amount of miRNA profiling data has been amassed in various cardiovascular disease models and patients, leading to current active clinical trials [73]. In heart failure patients, for example, profiling miRNA expression as biomarkers from patients receiving U.S. Food and Drug Administration (FDA)–approved medications has been described. Table 4 contains detailed information on miRNA investigations in clinical trials.
Conclusion
Myocarditis remains a challenge, and the recent COVID-19 outbreak has brought it back to the forefront. Although its exact pathophysiology remains unknown, new research is seeking to improve our understanding and lay the groundwork for newer treatment methods. MiRNAs offer further insights into this understanding.
Conflicts of interest
There is no conflict of interests to declare.
Funding
This work is supported by NRF-2020R1A2C1013377 and NRF-2017R1D1A1B03030852 for H Seok.
ReferencesFungGLuoHQiuYYangDMcManusBMyocarditis2016118496514DennertRCrijnsHJHeymansSAcute viral myocarditis200829207382CaforioALPankuweitSArbustiniEBassoCGimeno-BlanesJFelixSBCurrent state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases2013342636482648a-2648dD'AmbrosioAPattiGManzoliASinagraGDi LenardaASilvestriFThe fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review200185499504AretzHTMyocarditis: the Dallas criteria19871861924KociolRDCooperLTFangJCMoslehiJJPangPSSabeMARecognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association2020141e6992ChowLHRadioSJSearsTDMcManusBMInsensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis19891491520AnziniMMerloMSabbadiniGBarbatiGFinocchiaroGPinamontiBLong-term evolution and prognostic stratification of biopsy-proven active myocarditis2013128238494KindermannIKindermannMKandolfRKlingelKBultmannBMullerTPredictors of outcome in patients with suspected myocarditis200811863948CaforioALCalabreseFAngeliniATonaFVinciABottaroSA prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis200728132633VaidyaVRAbudanAAVasudevanKShanthaGCooperLTKapaSThe efficacy and safety of electroanatomic mapping-guided endomyocardial biopsy: a systematic review2018536371Global Burden of Disease Study CGlobal, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 20132015386743800CooperLTJrKerenASliwaKMatsumoriAMensahGAThe global burden of myocarditis: part 1: a systematic literature review for the Global Burden of Diseases, Injuries, and Risk Factors 2010 study201491219AmmiratiECiprianiMMoroCRaineriCPiniDSormaniPClinical presentation and outcome in a contemporary cohort of patients with acute myocarditis: multicenter lombardy registry2018138108899AmmiratiEVeroneseGBrambattiMMerloMCiprianiMPotenaLFulminant versus acute nonfulminant myocarditis in patients with left ventricular systolic dysfunction201974299311MaronBJUdelsonJEBonowRONishimuraRAAckermanMJEstes NA3rdEligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology2015132e27380PauschingerMPhanMDDoernerAKuehlUSchwimmbeckPLPollerWEnteroviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis19999988995AndreolettiLLevequeNBoulagnonCBrasseletCFornesPViral causes of human myocarditis200910255968BaruteauAEBoimondNRamfulDMyocarditis associated with 2009 influenza A (H1N1) virus in children2010203512BowlesNENiJKearneyDLPauschingerMSchultheissHPMcCarthyRDetection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults20034246672MatsumoriAYutaniCIkedaYKawaiSSasayamaSHepatitis C virus from the hearts of patients with myocarditis and cardiomyopathy200080113742OmuraTYoshiyamaMHayashiTNishiguchiSKaitoMHoriikeSCore protein of hepatitis C virus induces cardiomyopathy20059614850WinkKSchmitzHCytomegalovirus myocarditis198010066772ChenJHanZWuHXuWYuDZhangYA large-scale outbreak of echovirus 30 in Gansu Province of China in 2015 and its phylodynamic characterization2020111137RohayemJDingerJFischerRKlingelKKandolfRRethwilmAFatal myocarditis associated with acute parvovirus B19 and human herpesvirus 6 coinfection20013945857WatanabeMPanettaGLPiccirilloFSpotoSMyersJSerinoFMAcute Epstein-Barr related myocarditis: an unusual but life-threatening disease in an immunocompetent patient20202113740KaratoliosKMaischBPankuweitSSuspected inflammatory cardiomyopathy201540 Suppl 1915Marin-NetoJACunha-NetoEMacielBCSimoesMVPathogenesis of chronic Chagas heart disease2007115110923GravanisMBHertzlerGLFranchRHStacyLDAnsariAAKanterKRHypersensitivity myocarditis in heart transplant candidates1991105 Pt 168897MevorachDAnisECedarNBrombergMHaasEJNadirEMyocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel202138521409BardaNDaganNBalicerRDBNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply20213841970ArnessMKEckartRELoveSSAtwoodJEWellsTSEnglerRJMyopericarditis following smallpox vaccination200416064251HalsellJSRiddleJRAtwoodJEGardnerPShopeRPolandGAMyopericarditis following smallpox vaccination among vaccinia-naive US military personnel200328932839ParkHYunKWKimKRSongSHAhnBKimDREpidemiology and clinical features of myocarditis/pericarditis before the introduction of mRNA COVID-19 vaccine in Korean children: a multicenter study202136e232KimJChoMJAcute myocarditis in children: a 10-year nationwide study (2007-2016) based on the Health Insurance Review and Assessment Service Database in Korea202050101322SeokHOhJHHypertrophic cardiomyopathy in infants from the perspective of cardiomyocyte maturation20215173351BergmannOZdunekSFelkerASalehpourMAlkassKBernardSDynamics of cell generation and turnover in the human heart2015161156675AmmiratiEVeroneseGBottiroliMWangDWCiprianiMGarasciaAUpdate on acute myocarditis2021313709VerdonschotJHazebroekMMerkenJDebingYDennertRBrunnerLa RoccaHPRelevance of cardiac parvovirus B19 in myocarditis and dilated cardiomyopathy: review of the literature201618143041RoseNRLearning from myocarditis: mimicry, chaos and black holes2014625BratincsakAEl-SaidHGBradleyJSShayanKGrossfeldPDCannavinoCRFulminant myocarditis associated with pandemic H1N1 influenza A virus in children2010559289WangDHuBHuCZhuFLiuXZhangJClinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China202032310619GuoTFanYChenMWuXZhangLHeTCardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)202058118TavazziGPellegriniCMaurelliMBelliatoMSciuttiFBottazziAMyocardial localization of coronavirus in COVID-19 cardiogenic shock2020229115TschopeCCooperLTTorre-AmioneGVan LinthoutSManagement of myocarditis-related cardiomyopathy in adults2019124156883MahmoodSSFradleyMGCohenJVNohriaAReynoldsKLHeinzerlingLMMyocarditis in patients treated with immune checkpoint inhibitors201871175564HaslamAPrasadVEstimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs20192e192535Costanzo-NordinMRReapEAO'ConnellJBRobinsonJAScanlonPJA nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis19856107882SemmlerDBlankRRupprechtHComplete AV block in Lyme carditis: an important differential diagnosis20109951926MirabelMLuytCELeprincePTrouilletJLLegerPPavieAOutcomes, long-term quality of life, and psychologic assessment of fulminant myocarditis patients rescued by mechanical circulatory support201139102935RajagopalSKAlmondCSLaussenPCRycusPTWypijDThiagarajanRRExtracorporeal membrane oxygenation for the support of infants, children, and young adults with acute myocarditis: a review of the Extracorporeal Life Support Organization registry2010383827HufnagelGPankuweitSRichterASchonianUMaischBThe European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results20002527985McNamaraDMHolubkovRStarlingRCDecGWLohETorre-AmioneGControlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy200110322549DruckerNAColanSDLewisABBeiserASWesselDLTakahashiMGamma-globulin treatment of acute myocarditis in the pediatric population1994892527BulutDScheelerMWichmannTBorgelJMiebachTMuggeAEffect of protein A immunoadsorption on T cell activation in patients with inflammatory dilated cardiomyopathy2010996338WojniczRNowalany-KozielskaEWojciechowskaCGlanowskaGWilczewskiPNiklewskiTRandomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results20011043945FairweatherDKayaZShellamGRLawsonCMRoseNRFrom infection to autoimmunity20011617586LvHHavariEPintoSGottumukkalaRVCornivelliLRaddassiKImpaired thymic tolerance to alpha-myosin directs autoimmunity to the heart in mice and humans2011121156173MiricMVasiljevicJBojicMPopovicZKeserovicNPesicMLongterm follow up of patients with dilated heart muscle disease treated with human leucocytic interferon alpha or thymic hormones initial results199675596601GullestadLAassHAndreassenAKIhlenHSimonsenSKjekshusJImmunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin200112119027FrustaciAChimentiCCalabreseFPieroniMThieneGMaseriAImmunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders200310785763DennertRVelthuisSSchallaSEurlingsLvan SuylenRJvan PaassenPIntravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load201015193201BaughmanKLDiagnosis of myocarditis: death of Dallas criteria20061135935MatsumoriAIgataHOnoKIwasakiAMiyamotoTNishioRHigh doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity19996393440XiaoJShimadaMLiuWHuDMatsumoriAAnti-inflammatory effects of eplerenone on viral myocarditis20091134953WangWZMatsumoriAYamadaTShioiTOkadaIMatsuiSBeneficial effects of amlodipine in a murine model of congestive heart failure induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production19979524551HaMKimVNRegulation of microRNA biogenesis20141550924O'BrienJHayderHZayedYPengCOverview of MicroRNA biogenesis, mechanisms of actions, and circulation20189402ZhouSSJinJPWangJQZhangZGFreedmanJHZhengYmiRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges201839107384van RooijEKauppinenSDevelopment of microRNA therapeutics is coming of age2014685164CallisTEChenJFWangDZMicroRNAs in skeletal and cardiac muscle development20072621925KaurAMackinSTSchlosserKWongFLElharramMDellesCSystematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease2020116111324ViereckJThumTCirculating noncoding RNAs as biomarkers of cardiovascular disease and injury201712038199GrueterCEvan RooijEJohnsonBADeLeonSMSutherlandLBQiXA cardiac microRNA governs systemic energy homeostasis by regulation of MED13201214967183HeymansSErikssonULehtonenJCooperLTJrThe quest for new approaches in myocarditis and inflammatory cardiomyopathy201668234864CorstenMFPapageorgiouAVerhesenWCaraiPLindowMObadSMicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis201211141525YanLHuFYanXWeiYMaWWangYInhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response201694106379ZhangYZhangMLiXTangZWangXZhongMSilencing microRNA-155 attenuates cardiac injury and dysfunction in viral myocarditis via promotion of m2 phenotype polarization of macrophages2016622613NavarroICFerreiraFMNakayaHIBaronMAVilar-PereiraGPereiraIRMicroRNA transcriptome profiling in heart of trypanosoma cruzi-infected mice: parasitological and cardiological outcomes20159e0003828ZhaoSYangGLiuPNDengYYZhaoZSunTmiR-590-3p is a Novel MicroRNA in myocarditis by targeting nuclear factor kappa-B in vivo20151321828KuehlULassnerDGastMStrouxARohdeMSiegismundCDifferential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy2015860518CorstenMFDennertRJochemsSKuznetsovaTDevauxYHofstraLCirculating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease20103499506DevauxYVausortMGorettiENazarovPVAzuajeFGilsonGUse of circulating microRNAs to diagnose acute myocardial infarction20125855967CorstenMFHeggermontWPapageorgiouAPDeckxSTijsmaAVerhesenWThe microRNA-221/-222 cluster balances the antiviral and inflammatory response in viral myocarditis201536290919HeymansSCorstenMFVerhesenWCaraiPvan LeeuwenRECustersKMacrophage microRNA-155 promotes cardiac hypertrophy and failure2013128142032Blanco-DominguezRSanchez-DiazRde la FuenteHJimenez-BorregueroLJMatesanz-MarinARelanoMA novel circulating microRNA for the detection of acute myocarditis2021384201427StephensonMLZamecnikPCInhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide1978752858KristenAVAjroud-DrissSConceicaoIGorevicPKyriakidesTObiciLPatisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis20199523AdamsDGonzalez-DuarteAO'RiordanWDYangCCUedaMKristenAVPatisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis20183791121HannaJHossainGSKocerhaJThe potential for microRNA therapeutics and clinical research201910478CrookeSTWitztumJLBennettCFBakerBFRNA-targeted therapeutics20182771439SettenRLRossiJJHanSPThe current state and future directions of RNAi-based therapeutics20191842146HuBZhongLWengYPengLHuangYZhaoYTherapeutic siRNA: state of the art20205101KrutzfeldtJRajewskyNBraichRRajeevKGTuschlTManoharanMSilencing of microRNAs in vivo with 'antagomirs'20054386859LucasTBonauerADimmelerSRNA therapeutics in cardiovascular disease201812320520AbplanalpWTFischerAJohnDZeiherAMGosgnachWDarvilleHEfficiency and target derepression of anti-miR-92a: results of a first in human study20203033545TaubelJHaukeWRumpSViereckJBatkaiSPoetzschJNovel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study20214217888LiTDingZLZhengYLWangWMiR-484 promotes non-small-cell lung cancer (NSCLC) progression through inhibiting Apaf-1 associated with the suppression of apoptosis20179615364KumarswamyRVolkmannIBeermannJNappLCJabsOBhayadiaRVascular importance of the miR-212/132 cluster201435322431FoinquinosABatkaiSGenschelCViereckJRumpSGyongyosiMPreclinical development of a miR-132 inhibitor for heart failure treatment202011633van RooijESutherlandLBLiuNWilliamsAHMcAnallyJGerardRDA signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure20061031825560HoBCYuSLChenJJChangSYYanBSHongQSEnterovirus-induced miR-141 contributes to shutoff of host protein translation by targeting the translation initiation factor eIF4E201195869TongLLinLWuSGuoZWangTQinYMiR-10a* up-regulates coxsackievirus B3 biosynthesis by targeting the 3D-coding sequence201341376071LiaoYChenKHDongXMFangYLiWGHuangGYA role of pre-mir-10a coding region variant in host susceptibility to coxsackie virus-induced myocarditis20151935007XuHFDingYJShenYWXueAMXuHMLuoCLMicroRNA-1 represses Cx43 expression in viral myocarditis20123621418YeXHemidaMGQiuYHansonPJZhangHMYangDMiR-126 promotes coxsackievirus replication by mediating cross-talk of ERK1/2 and Wnt/beta-catenin signal pathways201370463144WuJShenLChenJXuHMaoLThe role of microRNAs in enteroviral infections2015195106SunPWangNZhaoPWangCLiHChenQCirculating exosomes control CD4(+) T cell immunometabolic functions via the transfer of mir-142 as a novel mediator in myocarditis202028260520Figure and Tables
Myocarditis occurrence comparison (Korea, USA, and Israel)